Most Popular
-
1
Now is no time to add pressure on businesses: top executives
-
2
CJ CheilJedang to spur overseas growth with new Hungary, US plants
-
3
Seoul to host winter festival from Dec. 13
-
4
Nationwide rail disruptions feared as union plans strike from Dec. 5
-
5
Blackpink's solo journeys: Complementary paths, not competition
-
6
N. Korea, Russia court softer image: From animal diplomacy to tourism
-
7
[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
-
8
Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid
-
9
Korean Air offers special flights for mileage users
-
10
Defense ministry denies special treatment for BTS’ V amid phone use allegations
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
Kolon Life Science seeks approval for degenerative arthritis drug
By Ahn Sung-miPublished : July 12, 2016 - 14:58
[THE INVESTOR] Kolon Life Science has filed for government approval for a drug it developed to treat degenerative arthritis, the company said on July 11.
After 17 years of research, the pharmaceutical company introduced Invossa, Korea’s first gene therapy for degenerative arthritis.
The new drug injects healthy human cartilage cells into the space between the bones to alleviate pain and treat the major symptoms. It can also be an alternative for surgical treatment, according to Kolon Life Science.
Once the drug is approved by the Ministry of Food and Drug Safety, it can hit the shelves as early as the first half of 2017. The company also plans to carry out phase-III clinical trials for approval in the US next year.
By Ahn Sung-mi (sahn@heraldcorp.com)
After 17 years of research, the pharmaceutical company introduced Invossa, Korea’s first gene therapy for degenerative arthritis.
The new drug injects healthy human cartilage cells into the space between the bones to alleviate pain and treat the major symptoms. It can also be an alternative for surgical treatment, according to Kolon Life Science.
Once the drug is approved by the Ministry of Food and Drug Safety, it can hit the shelves as early as the first half of 2017. The company also plans to carry out phase-III clinical trials for approval in the US next year.
By Ahn Sung-mi (sahn@heraldcorp.com)
![[Today’s K-pop] Babymonster logs 100m views with ‘Drip’ music video](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/11/22/20241122050051_0.jpg&u=20241122172213)